Ashwin N. Ananthakrishnan
YOU?
Author Swipe
View article: Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age Open
Background Older adults with ulcerative colitis (UC) have unique treatment challenges. Ozanimod is approved for the treatment of moderately to severely active UC in adults based on the phase 3 True North (TN) study results. Here, we analyz…
View article: Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study
Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study Open
Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patie…
View article: Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases
Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases Open
Importance Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions. Objective To compare the risk of adverse eve…
View article: Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid Open
Background We evaluated the efficacy and safety of ozanimod after 5-aminosalicylic acid (5-ASA) failure in advanced therapy (AT)–naive patients with moderate ulcerative colitis (UC) in True North and its open-label extension (OLE). Methods…
View article: Serum proteomic and metabolomic analyses from patients with <scp>IBD</scp> identify biological pathways associated with treatment success with anti‐integrin therapy
Serum proteomic and metabolomic analyses from patients with <span>IBD</span> identify biological pathways associated with treatment success with anti‐integrin therapy Open
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise from an imbalance between its epithelial, immune and microbial components. It has been shown that biological…
View article: Diagnosis of Inflammatory Bowel Disease–Associated Peripheral Arthritis: A Systematic Review
Diagnosis of Inflammatory Bowel Disease–Associated Peripheral Arthritis: A Systematic Review Open
BACKGROUND: Inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA) decreases quality of life and remains poorly understood. Given the prevalence of this condition and its negative impact, it is surprising that evid…
View article: Transcriptome Profiling and Viral−Human Interactome Insights Into HBV‐Driven Oncogenic Alterations in Hepatocellular Carcinoma
Transcriptome Profiling and Viral−Human Interactome Insights Into HBV‐Driven Oncogenic Alterations in Hepatocellular Carcinoma Open
Hepatocellular carcinoma (HCC) is the primary form of liver cancer that poses a significant global health concern due to its increasing incidence rates and diverse etiology. Chronic infection induced by hepatitis B virus (HBV) is a promine…
View article: Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health
Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health Open
The pathogenesis of inflammatory bowel disease (IBD) involves a complex interplay between genetic, environmental, and microbial factors. Many of these environmental determinants are modifiable, offering opportunities to prevent disease or …
View article: Dietary Nut and Legume Intake and Risk of Crohn’s Disease and Ulcerative Colitis
Dietary Nut and Legume Intake and Risk of Crohn’s Disease and Ulcerative Colitis Open
Background We investigated the relationship between nut and legume intake and risk of Crohn’s disease (CD) and ulcerative colitis (UC). Methods We conducted a prospective cohort study of 223 283 adults from the Nurses’ Health Study (NHS), …
View article: Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial Open
Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an adv…
View article: Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease
Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease Open
Data indicate that earlier initiation of anti-tumor necrosis factor alpha (anti-TNF-α) biologic medicines may prevent progression to irreversible bowel damage and improve outcomes for patients with inflammatory bowel disease (IBD), particu…
View article: Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis
Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis Open
Background Historically, randomized controlled trials (RCTs) have been criticized for being poorly generalizable to patients with ulcerative colitis (UC) evaluated in routine care. We aimed to evaluate the proportion of patients with UC st…
View article: The Ulcerative Colitis-Associated Gene NXPE1 Catalyzes Glycan Modifications on Colonic Mucin
The Ulcerative Colitis-Associated Gene NXPE1 Catalyzes Glycan Modifications on Colonic Mucin Open
Colonic mucus forms a first line of defense against bacterial invasion while providing nutrition to support coinhabiting microbes in the gut. Mucus is composed of polymeric networks of mucin proteins, which are heavily modified post-transl…
View article: Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997–2020
Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997–2020 Open
Approximately one-fourth of individuals with mild UC within 1 year after diagnosis and one-half of those with mild CD progressed to moderate-severe disease over time. Young age at diagnosis increased the probability of progression, whereas…
View article: Association of Childhood Abuse With Incident Inflammatory Bowel Disease
Association of Childhood Abuse With Incident Inflammatory Bowel Disease Open
INTRODUCTION: A link between inflammatory bowel disease (IBD), stressful life events, and psychological factors has previously been reported. Our objective was to examine the relationship between emotional, physical, and sexual abuse of ch…
View article: Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort
Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort Open
Background and Aims Acute severe ulcerative colitis (UC) (ASUC) requiring hospitalization affects up to 1 in 4 patients with UC. There is a paucity of prospective and multicenter clinical cohorts to study treatment trends and predictors of…
View article: Meta‐analysis: Risk of lymphoma in patients with inflammatory bowel disease in population‐based cohort studies
Meta‐analysis: Risk of lymphoma in patients with inflammatory bowel disease in population‐based cohort studies Open
Summary Background There are inconsistencies in the results of the studies investigating the association between inflammatory bowel disease (IBD) and lymphoma. Aims The aim of this study is to systematically appraise the risk of lymphoma d…
View article: A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease Open
The inflammatory bowel diseases (IBD) known as Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise because of an imbalance between the epithelial, immune and mi…
View article: Diet and Microbiome-Directed Therapy 2.0 for IBD
Diet and Microbiome-Directed Therapy 2.0 for IBD Open
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that …
View article: Challenges in IBD Research 2024: Environmental Triggers
Challenges in IBD Research 2024: Environmental Triggers Open
Environmental factors play an important role in inflammatory bowel diseases (IBD; Crohn’s disease, [CD], ulcerative colitis [UC]). As part of the Crohn’s & Colitis Challenges 2024 agenda, the Environmental Triggers workgroup summarized the…